悦康药业:子公司YKYY018雾化吸入剂获FDA临床试验批准

智通财经
Nov 12
【悦康药业:子公司YKYY018雾化吸入剂获FDA临床试验批准】悦康药业公告称,公司子公司悦康科创近日获得美国FDA批准,同意YKYY018雾化吸入剂用于治疗与预防人副流感病毒感染的临床试验申请,IND编号183460。YKYY018雾化吸入剂为公司依托全流程AI平台自主开发的国际原创膜融合抑制剂药物,此前已获FDA及NMPA批准开展针对呼吸道合胞病毒、人偏肺病毒感染的临床试验,目前其针对呼吸道合胞病毒感染的II期临床研究正在推进中。本次获批进一步拓展了该产品在呼吸道病毒感染防治领域的临床开发布局,药品后续研发及审批结果存在不确定性。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10